Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 14, 2023 8:46pm
347 Views
Post# 35588135

From todays Q2 update

From todays Q2 update

Todays call was medium in length. A couple of Q & A.
Brought forward today, aside from the well known MBc & Pancreatic trial background.
1. since ASCO additional pharma companies have expressed business development interests with Onc.
2. There are still on- going CAR-T projects with pharmas/ Pela.
3. They have cashrunway near end if 2024.
4. Paperwork in in progress for Panc/ PanCan trial. The existing sites & protocols will ensure smooth progress once started.
5. Based on # 4 they are in talks with pharma for potential partners.
5a. They did say, we are in no rush & are working to create a competitive environment.
6. The recent offering was taken up by an institutional investor, specializing in the medical area.
7. The MBc trial? Bracelet is still showing progress. They did say still moving ahead, just not unrgency, due to some additional definitions of the requirements. 

8 next big reveal would appear to be forthcoming october cancer conference.
being inclusive of goblet, panc & mbc

9. The CAR-t?
could be tomorrow or 20 years from now. 

My cometary?
The most significant of all this , the $15mill buy- in of an institution.
They don't do that to loose. They think longer term.
The Nas does disclose institutional investors. Not sure about TSX ?
perhaps, some of our inquisitive minds can find out?
 

S.P.
apparently we are at a recent significantly higher short % than in a very long time,
GREAT!
next up- cycle , will not have any ATM , & shorts will need to cover.
Stay safe & healthy. Have a great week all.
 

<< Previous
Bullboard Posts
Next >>